Isoniazid- and rifampicin-induced thrombocytopenia

Isoniazid- and rifampicin-induced thrombocytopenia

Authors

  • Fatih Yakar Department of Pulmonary Medicine, Bezmialem Vakif University, 34093, Fatih, Istanbul
  • Namşan Yildiz Department of Pulmonary Medicine, IstanbulUniversity, Istanbul Medical Faculty, Istanbul
  • Aysun Yakar Department of Pulmonary Medicine, Malatya State Hospital, Malatya
  • Zeki Kılıçaslan Department of Pulmonary Medicine, IstanbulUniversity, Istanbul Medical Faculty, Istanbul

Keywords:

Drug toxicity, Thrombocytopenia, Tuberculosis

Abstract

Treatment of tuberculosis has many side effects. Thrombocytopenia is a serious side effect of such treatment and occurs mostly due to rifampicin (RIF). There are very few reported cases of thrombocytopenia due to isoniazid (INH). An 18-year-old female patient was diagnosed with smear-positive pulmonary tuberculosis. A four-drug regimen [INH, RIF, ethambutol (EMB), and pyrazinamide (PZA)] was given. After the development of thrombocytopenia, the drug treatment was stopped, and a thrombocyte suspension was given until a normal thrombocyte count was obtained. After several start-stop trials, first INH and then RIF were identified as the possible causes of thrombocytopenia and were removed from the regimen. The patient was treated with EMB, streptomycin, PZA, and moxifloxacin with no further development of thrombocytopenia. The current case shows that antituberculosis drugs other than RIF and PZA may be responsible for the development of thrombocytopenia.

Downloads

Published

13-02-2013

Issue

Section

Case Reports

How to Cite

1.
Yakar F, Yildiz N, Yakar A, Kılıçaslan Z. Isoniazid- and rifampicin-induced thrombocytopenia. Multidiscip Respir Med [Internet]. 2013 Feb. 13 [cited 2024 Jul. 4];8(9). Available from: https://mrmjournal.org/index.php/mrm/article/view/482